A detailed history of Clearstead Advisors, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Clearstead Advisors, LLC holds 2,425 shares of EXAS stock, worth $140,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,425
Previous 2,663 8.94%
Holding current value
$140,916
Previous $112,000 47.32%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$42.43 - $70.83 $10,098 - $16,857
-238 Reduced 8.94%
2,425 $165,000
Q2 2024

Aug 09, 2024

BUY
$41.33 - $74.26 $9,836 - $17,673
238 Added 9.81%
2,663 $112,000
Q1 2020

May 14, 2020

SELL
$37.9 - $104.44 $720 - $1,984
-19 Reduced 0.78%
2,425 $141,000
Q4 2019

Feb 11, 2020

BUY
$77.66 - $99.74 $1,475 - $1,895
19 Added 0.78%
2,444 $226,000
Q1 2019

May 14, 2019

BUY
$61.98 - $96.5 $150,301 - $234,012
2,425 New
2,425 $210,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Clearstead Advisors, LLC Portfolio

Follow Clearstead Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.